Secondary prevention of heart disease amongst patients with lipid abnormalities: Practice and trends in the United States

Journal of Internal Medicine

Volumn 241, Issue 4, 1997, Pages 283-294

  Brown, B G ^a   Zhao, Xue Qiao ^a   Bardsley, J ^a   Albers, J J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; HEALTH PROMOTION; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL; PROPHYLAXIS; REVASCULARIZATION; SECONDARY PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES;

EID: 0031006955     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.109132000.x     Document Type: Conference Paper

References (62)

1. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
2. Brown BG, Fuster V. Impact of management in stabilization of coronary disease. In: Atherosclerosis and Coronary Artery disease. Fuster V, Ross R, Topol EJ, Eds. Lippincott-Raven, Philadelphia 1996; 191-205.
3. Brown BG, Maher VMG. Reference list. Reversal of coronary heart disease by lipid-lowering therapy; Observations and pathological mechanisms. Circulation 1994: 89(6): 2928-33.
4. Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: Operative technique. Ann Thorac Surg 1968; 5: 334-9.
5. CASS Principal Investigators and their associates. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery: survival data. Circulation 1983; 68: 939-50.
6. Gruentzig A. Transluminal dilation of coronary-artery stenosis. Lancet 1978; 1: 263.
7. King SB III, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart H-X, Zhao X-Q et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med 1994; 331: 1044-50.
8. Powck SJ, Henderson RA, Richards AF, Hampton JR, King SB III. Hamm CW et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346: 1184-9.
9. Aldridge HE, Trimble AS. Progression of proximal coronary artery disease to total occlusion after aorta-coronary saphenous vein bypass grafting. J Thoracic Cardiovasc Surg 1971: 62: 7-11.
10. Brown BG, Cukingnan RA, Peterson RB, Pierce CD, Bolson EL, Dodge HT. Perianastomotic arteriosclerosis in grafted human coronary arteries. Prevention with platelet-inhibiting therapy. (abstr.) Am J Cardiol 1982; 47: 968.
11. Fitzgibbon GM, Leach AJ, Kafka HP, Keon WF. Coronary bypass graft fate: long-term angiographic study. J Am Coll Cardiol 1991; 17: 1075-80.
12. Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P, Wachtolder S et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. N Engl J Med 1984; 311: 1329-32.
13. Pekkanen J, Linn S, Heise G, Suchindron CM, Leon A, Rifkind BM et al. Ten year mortality from cardiovascular disease in relation to cholesterol level in men with and without pre-existing cardiovascular disease. N Engl J Med 1990; 322: 1700-7.
14. Parisi AF, Folland ED, Hartigon P, on behalf of the Veterans Affairs ACME investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992; 326: 10-16.
15. Brown BG, Cukingnan RA, DeRouen T, Goede LV, Wong M, Fee HJ et al. Improved graft patency in patients treated with platelet inhibiting therapy after coronary bypass surgery. 1986; Circulation 72: 138-16.
16. Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984; 310: 210.
17. The Veterans Administration Coronary Bypass Surgery Cooperative Study Group. Eleven-year survival in the VA randomized trial of coronary bypass surgery for stable angina. N Engl J Med 1984; 311: 1333-9.
18. Varnauskas E. Twelve year follow-up of survival in the Randomized European coronary Surgery Study. N Engl J Med 1988; 319: 332-7.
19. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
20. Lewis HD, for the Veterans Administration Cooperative Study Group. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 304: 396-403.
21. Theroux P, Ouimet H, McCans J, LaTour J, Joly P, Levy G et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
22. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2, Lancet 1988; ii: 350-60.
23. The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980; 62: 449.
24. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men: the Lipid Research Clinics mortality follow-up study. N Engl J Med 1988; 319: 1379-84.
25. Blair SN, Kohl HW III. Paffenbarger RS, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA 1989: 262: 2395-401.
26. Oberman A. Rehabilitation of patients with coronary artery disease. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 3rd ed. Philadelphia: W.B. Saunders, 1988: 395-109.
27. Sacks F, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994; 344: 1182-6.
28. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Boccuzzi JJ, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-68.
29. Sacks FM, Pfeffer MA, Braunwald E, and The CARE Investigators. Cholesterol and Recurrent Events Trial. Preliminary results. Presented at Scientific Sessions. American College of Cardiology, Orlando, FL, March 25, 1996.
30. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cachin-Hamphill L. Beneficial effects of colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40
31. Brown BG, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
32. Stewart BF, Brown BG, Qiao X-Q, Hillger LA, Sniderman AD, Dowdy A et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994; 23: 899-906.
33. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007.
34. Alderman E, Haskell WL, Fain JM, Superko HR, Maron DJ, Champagne MA et al. Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP) (Abstract). Circulation 1991; 84 (Suppl II): II-140.
35. Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, Dodge HT. In complete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: Quantitative angiographic observations. Circulation 1986; 73: 653-61.
36. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62.
37. Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 1990; 66: 44-7G.
38. Constantinides P. Plaque hemorrhages, their genesis and their role in supra-plaque thrombosis and atherogenesis. In: Pathobiology of the Human Atherosclerotic Plaque. Glagov S, Newman WP, Schaffer SA, eds. Springer-Verlag, New York 1990; 393-411.
39. Lendon CL, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991; 87: 87-90.
40. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; iii: 941-44.
41. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
42. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture. Circulation 1994; 90: 775-8.
43. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembrey R, Murphy G, Humphries S. Location of stromelysin gene in atherosclerotic plaques using in-site hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8.
44. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophages, and smooth muscle cell content. Br Heart J 1993; 69: 377-81.
45. Maher VMG, Brown BG, Marcovina SM, Sacco D, Lin JT, Hillger LA et al. The adverse effect of lipoprotein (a) on coronary atherosclerosis and clinical events is eliminated by substantially lowering LDL cholesterol (Abstract). JACC 1994.
46. National Center for Health Statistics. Development of the design of the NCHS Hospital Discharge Survey. Vital and Health Statistics. PHS Pub. No. 1000 Series 2, No. 39. Public Health Service, Washington : U.S. Government Printing Office, 1970.
47. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G et al. Intracoronary stenting without anticoagulation, accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-88.
48. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148: 36-69.
49. Expert Panel on Detect, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 1993; 269: 3015-23.
50. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE et al. Effect of coptopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction : results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
51. Yusef S, Pepine CJ, Garcea C, Pouleur H, Salmen D, Kostis J et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.
52. Beta-blocker Heart Attack Trial Research Group. A randomized trial of proprenolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-14.
53. Brown BG, Zhao X-Q, Maher VMG, Chait A, Cheung M, Fisher LD et al. HDL-c as a therapeutic target in coronary disease: Current concepts and future direction. In: HDL Deficiency and Atherosclerosis, Assman G. Ed. (Developments in Cardiovascular Medicine. Vol. 174) Kluwer Academic Publishers, Dordrecht, 1995; 29-42.
54. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15.
55. Anonymous. Use of cholesterol-lowering drugs, United States, 1992 (Editorial). Statistical Bulletin 1993; 74: 10-17.
56. Cohen MV, Byrne MJ, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83: 1294-304.
57. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ et al. Preventing heart attack and death in patients with coronary disease. AHA Consensus Panel Statement. Circulation 1995; 92: 2-4.
58. Nieto FJ, Alonso J, Chambless LE, Zhong M, Ceraso M, Romm FJ et al. Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities Study. Arch Intern Med 1995; 155: 677-84.
59. Giles WH, Anda RF, Jones DH, Jerdula MK, Merritt RK, DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities. JAMA 1993; 269: 1133-8.
60. IMS America Ltd. National Prescription Audit. Plymouth Meeting, PA: IMS America, 1992.
61. Anonymous. Heart disease mortality: International comparisons. Statistical Bulletin 1993; 74: 19-26.
62. Johnson CL, Rifkind BM, Sampros CT, Carroll MD, Bachorik PS, Briefel RR et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002-8.